Introduction
============

Breast cancer, as the most prevalent cancer among women,[@b1-cmar-10-1969] has been associated with a significant mortality rate.[@b2-cmar-10-1969] Despite much research,[@b3-cmar-10-1969]--[@b5-cmar-10-1969] only few biomarkers or therapeutic targets have been approved, altering the ordinary practice of oncology.[@b6-cmar-10-1969] Therefore, continuous efforts are being made in the field of identification of biomarkers for this type of human malignancy. Neuropilin-1 (NRP1) as an isoform-specific receptor for vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) in endothelial cells has been demonstrated to be expressed in breast cancer cells where it plays functional roles in cell survival, invasion, and migration.[@b7-cmar-10-1969] In the context of cancer, NRP1 also regulates angiogenesis and the epithelial-to-mesenchymal transition (EMT) mechanisms through interactions with VEGF, and its receptors, PlGF and transforming growth factor β 1 (TGF-β1).[@b8-cmar-10-1969] Moreover, NRP1 has been shown to be a target of regulation by the tumor suppressor miR-206 in estrogen receptor-positive cell lines, MCF-7 and T47D. The inhibitory effects of miR-206 overexpression on the migration and invasive potentials of these cells are at least partly due to its suppressive effect on NRP1 expression.[@b9-cmar-10-1969] Taken together, these data suggest an oncogenic role for NRP1 in the pathogenesis of breast cancer and pinpoint it as a target of a functional tumor-suppressive microRNA (miRNA). Therefore, we designed a study to assess NRP1 expression at both RNA and protein levels in correlation with expression level of miR-206. We also extracted microarray gene expression data to compare those results with our expression data results.

Materials and methods
=====================

Patients' samples
-----------------

The expression study was performed on 48 tumoral tissues and their corresponding adjacent noncancerous tissues (ANCTs) obtained during surgery from patients with a definite diagnosis of invasive ductal carcinoma of the breast. Normal-appearing adjacent breast tissues were excised at least 2 cm away from the invasive tumor margin and were assessed by the pathologist to not contain tumoral cells. Tissues were obtained from Sina Hospital and Farmanieh Hospital (Tehran, Iran) during 2017. All patients signed an informed consent form. It was confirmed that the patients did not receive any kind of anticancer treatment before the surgery. The study protocol was approved by the ethical committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.MSP.REC.1396.153).

RNA extraction and real-time polymerase chain reaction (PCR)
------------------------------------------------------------

Total RNA was extracted from all samples using the TRIzol™ Reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to the protocol provided by the company. cDNA was synthesized from extracted RNA samples using RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). Relative transcript levels of *NRP1* were quantified using SYBR® Premix Ex Taq™ (TaKaRa, Otsu, Japan) on the Rotor Gene 6000 Corbett Real-Time PCR system. *B2M* gene was used as the normalizer. All experiments were carried out in duplicate. The nucleotide sequences of primers used for amplification of *NRP1* and *B2M* are as follows: *NRP1* forward primer: 5′-CTCCAACGGGGAAGACTGGA-3′, reverse primer: 5′-GTTGCAGGCTTGATTCGGAC-3′; *B2M* forward primer: 5′-AGATGAGTATGCCTGCCGTG-3′, reverse primer: 5′-GCGGCATCTTCAAACCTCCA-3′.

NRP1 tissue concentration
-------------------------

NRP1 tissue concentration was evaluated using the human NRP1 enzyme-linked immunosorbent assay (ELISA) kit (MyBiosource, San Diego, CA, USA) which uses the biotin double-antibody sandwich technology. The values of NRP1 are shown in pg/mL and defined as mean ± standard error of mean.

Extraction of microarray data
-----------------------------

We retrieved GSE5926 and GSE5927 microarray gene expression data through application of the Gene Expression Omnibus repository at the National Center for Biotechnology Information archives.[@b10-cmar-10-1969] Expression of *NRP1* gene was compared between breast cancer patients and normal samples using the GEO2R web tool (<https://www.ncbi.nlm.nih.gov/geo/info/geo2r.html>). Finally, we evaluated the correlations between expression of *NRP1* and expression of miR-206 as a validated regulator of *NRP1* in the mentioned microarray datasets.

Statistical analysis
--------------------

R software (version 3.3.1; Vienna, Austria) was used for statistical analysis. Data were presented as mean ± standard deviation. Differences in NRP1 mRNA expression were evaluated using Student's paired *t*-tests and Wilcoxon signed-rank test based on the presence or absence of normal distribution in data, respectively. The association of clinicopathological and demographic data with expression levels of NRP1 was evaluated using a chi-squared test, Student's *t*-test and one-way analysis of variance. The value of 2^−ΔΔCt^ was estimated to calculate the expression fold change for each gene. The cutoffs of the fold change values were calculated based on the median values of fold changes. Spearman's rank correlation coefficient was used for evaluation of the correlations between NRP1 protein concentration and relative expression of its mRNA and miR-206. For all statistical tests, the level of significance was set at *P*\<0.05.

Results
=======

General demographic and clinical data of patients
-------------------------------------------------

The current study included 48 patients with invasive ductal carcinomas of the breast whose detailed demographic and clinical data are shown in [Table 1](#t1-cmar-10-1969){ref-type="table"}.

Relative expression of NRP1 in tumoral tissues compared with ANCTs
------------------------------------------------------------------

No significant difference was found in *NRP1* expression between tumoral tissues and ANCTs ([Figure 1](#f1-cmar-10-1969){ref-type="fig"}).

We also assessed the associations between expression levels of *NRP1* and clinicopathological data of patients and found no significant associations between *NRP1* transcript levels and any characteristic ([Table 2](#t2-cmar-10-1969){ref-type="table"}).

Assessment of NRP1 protein concentrations
-----------------------------------------

NRP1 protein levels were quantified using a commercial ELISA kit in different subgroups of tumoral samples. [Table 3](#t3-cmar-10-1969){ref-type="table"} demonstrates the mean values of its expression in relation to patients' clinicopathological data. NRP1 protein concentrations were significantly higher in patients with lymph node involvement compared with those without lymph node involvement (*P*=0.03). However, NRP1 protein concentrations were not associated with other clinicopathological or demographic data.

Assessment of *NRP1* expression in GSE5926 dataset
--------------------------------------------------

We also evaluated *NRP1* expression levels in GSE5926 data-set and found significant downregulation of *NRP1* in in situ tumors compared with normal sample (*P*=0.02). However, no significant difference was found in its expression between invasive and in situ tumors (*P*=0.35) or between invasive and normal tissues (*P*=0.11) ([Table 4](#t4-cmar-10-1969){ref-type="table"}).

We also compared *NRP1* expression in different molecular subtypes of breast tumors and normal sample and found significant downregulation of *NRP1* in human epidermal growth factor receptor 2-positive, basal-like, luminal A and luminal B subtypes compared with normal sample. However, NRP1 expression was not significantly different between normal-like breast tumor and normal samples ([Table 5](#t5-cmar-10-1969){ref-type="table"}).

Assessment of correlation between *NRP1* and miR-206 expressions
----------------------------------------------------------------

We also retrieved data of miR-206 expression from the same cohort of patients (Seifi et al, unpublished data, 2017) and assessed the correlations between NRP1 expression levels and those of miR-206. No significant correlation was found between miR-206 and NRP1 transcript levels (Spearman's correlation coefficient =−0.0004, *P*=0.92) or between miR-206 and NRP1 protein levels (Spearman's correlation coefficient =−0.140, *P*=0.469). Also, the same analysis in the microarray datasets showed no correlation between transcript levels of miR-206 and NRP1 (Spearman's correlation coefficient =−0.004, *P*=0.98). In addition, no correlation was found between mRNA and protein levels of NRP1 (Spearman's correlation coefficient =−0.111, *P*=0.544).

Discussion
==========

In this study, we compared the expression of *NRP1* transcript between breast tumor tissues and ANCTs and found no significant difference in its expression levels between these sets of samples. We also retrieved gene expression data from GSE5926 dataset and found significant downregulation of *NRP1* in in situ tumors compared with normal sample but no significant difference in its expression between invasive and in situ tumors or between invasive and normal tissues. Our results are in contrast with Ferrario et al's study, which, through immunohistochemical staining of a breast tissue microarray, has shown significantly higher expression of NRP1 in malignant epithelium compared with benign and preinvasive breast lesions.[@b7-cmar-10-1969] Such inconsistency between our experimental results and the results of the mentioned study might be due to the difference in selection of control tissues (ANCTs vs. normal tissues). Aran et al recently assessed the transcriptomes of healthy tissues, ANCTs, and tumor tissues.[@b11-cmar-10-1969] They found that ANCTs show a distinctive intermediate expression profile between healthy and tumor tissues. More importantly, they observed activation of genes related to hypoxia, tumor necrosis factor α and TGF-β signaling, apoptosis, EMT, and angiogenesis in adjacent epithelium. Consequently, a relatively similar expres sion of NRP1 in tumoral tissues and ANCTs, as revealed in our study, as well as the similar expression of *NRP1* in invasive and in situ tumors, as obtained from analysis of microarray dataset, might be explained by activation of the mentioned pathways in ANCTs. However, due to the low number of normal tissues in the GSE5926 dataset,[@b12-cmar-10-1969] the analysis between normal tissues and other types of tissues might be biased.

Noticeably, we found significantly higher expression of NRP1 in lymph node-positive patients compared with lymph node-negative patients. We also detected a trend toward higher NRP1 levels in higher stages and histological grades, but perhaps due to the small sample size, it did not reach the level of significance. Such observation is in line with previous assays which showed the role of another receptor for VEGF, NRP2, in cell migration and metastasis.[@b13-cmar-10-1969] Moreover, in vivo and in vitro studies have indicated the effectiveness of NRP1 inhibition in suppression of breast-cancer-related metastasis.[@b14-cmar-10-1969] More recently, higher plasma NRP1 levels were detected in breast cancer patients with advanced diseased nodes compared with patients with no nodal metastasis, those with less advanced nodal metastasis, and healthy subjects.[@b8-cmar-10-1969]

Finally, we assessed the correlation between the mRNA and protein levels of NRP1 as well as those of NRP1 and miR-206 and found no correlation between any of them. The lack of correlation between mRNA and protein levels of a certain gene has been reported previously.[@b15-cmar-10-1969] A more recent study showed that mRNA and protein levels do not correlate well except when a gene-specific RNA-to-protein conversion factor is applied to improve the predictability of protein copy numbers from transcript levels.[@b16-cmar-10-1969] The dimensional and chronological alterations of mRNAs, along with the regional accessibility of resources for protein production, would affect the correlation between transcript and protein levels of a certain gene in many situations such as cancer.[@b17-cmar-10-1969]

Despite the fact that NRP1 has been validated as a target of miR-206 in cell line studies,[@b9-cmar-10-1969] both in silico analysis of microarray data and assessment of our gene expression results showed no correlation between NRP1 and miR-206 levels. This observation can be explained by the inhibitory effect of several miRNAs on NRP1 expression. To provide evidence for such hypothesis, we used the miRWalk2.0 tool[@b18-cmar-10-1969] to obtain the list of miRNAs that target NRP1 based on evaluation of miRNA-binding sites within the complete sequence of *NRP1*, as well as search for experimentally verified miRNA--NRP1 interaction data. We found that numerous miRNAs including miR-181, miR-335, miR-124, miR-16, miR-186, miR-218, miR-338, and miR-320 target NRP1. Therefore, the expression level of NRP1 is influenced by numerous factors. Besides, in silico analysis of National Cancer Institute-60 expression data has revealed more negative correlations between miRNA and mRNA expression profiles in cases where the miRNA degrades the corresponding mRNA compared with situations when the miRNA inhibits the translation of its target gene.[@b19-cmar-10-1969] Therefore, the lack of correlation between miR-206 and NRP1 levels can be explained by the possible effect of miR-206 on translation of NRP1. Future studies are needed to elaborate the underlying mechanism.

Conclusion
==========

This study provides evidence for superiority of protein levels over mRNA levels of NRP1 as a predictive marker in breast cancer. NRP1 protein levels might be an indicator of metastasis potential in breast cancer. Future studies are needed to confirm these results in larger cohorts of patients.
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###### 

General demographic and clinical data of patients

  Variables                   Groups     Number of cases (%)
  --------------------------- ---------- ---------------------
  Age (years)                 \<50       21 (44)
                              ≥50        27 (56)
  Body mass index (kg/m^2^)   \<25       2 (4)
                              25--29     24 (50)
                              \>29       22 (46)
  Menopause status            Post       37 (77)
                              Pre        11 (23)
  Stage                       I          11 (23)
                              II         18 (37.5)
                              III        16 (33)
                              IV         3 (6.5)
  Histological grade          I          7 (14.5)
                              II         25 (52)
                              III        16 (33.5)
  Mitotic rate                1          19 (39.5)
                              2          22 (46)
                              3          7 (14.5)
  Tumor size (cm)             \<2        18 (37.5)
                              2--5       22 (46)
                              \>5        8 (16.5)
  Lymph node involvement      Positive   19 (39.5)
                              Negative   29 (60.5)
  HER2 status                 Positive   36 (75)
                              Negative   12 (25)
  ER status                   Positive   37 (77)
                              Negative   11 (23)
  PR status                   Positive   35 (73)
                              Negative   13 (27)

**Abbreviations:** HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, progesterone receptor.

###### 

Association of *NRP1* transcript levels with patients' clinicopathological data

  Variable                    Number of cases   *NRP1* high level   *P*-value
  --------------------------- ----------------- ------------------- -----------
  Age (years)                                                       
   \<50                       21 (44%)          11                  NS
   ≥50                        27 (56%)          17                  
  Body mass index (kg/m^2^)                                         
   25--29                     24 (50%)          14                  NS
   \>29                       22 (46%)          13                  
  Menopause status                                                  
   Post                       37 (77%)          21                  NS
   Pre                        11 (23%)          7                   
  Stage                                                             
   I                          11 (23%)          4                   NS
   II                         18 (37.5%)        14                  
   III                        16 (33%)          6                   
   IV                         3 (6.5%)          2                   
  Histological grade                                                
   I                          7 (14.5%)         4                   NS
   II                         25 (52%)          15                  
   III                        16 (33.5%)        7                   
  Mitotic rate                                                      
   1                          19 (39.5%)        10                  NS
   2                          22 (46%)          10                  
   3                          7 (14.5%)         6                   
  Tumor size (cm)                                                   
   ≤2                         18 (37.5%)        9                   NS
   2--5                       22 (46%)          12                  
   ≥5                         8 (16.5%)         5                   
  Lymph node involvement                                            
   Positive                   19 (39.5%)        10                  NS
   Negative                   29 (60.5%)        16                  
  HER2                                                              
   Positive                   25 (75%)          16                  NS
   Negative                   23 (25%)          10                  
  ER                                                                
   Positive                   37 (77%)          21                  NS
   Negative                   11 (23%)          5                   
  PR                                                                
   Positive                   35 (73%)          19                  NS
   Negative                   13 (27%)          7                   
  Breast cancer phenotype                                           
   Luminal A                  19 (39.5%)        11                  0.891
   Luminal B                  22 (46%)          13                  
   HER2                       2 (4%)            1                   
   Triple negative            5 (10.5%)         3                   

**Note:** *NRP1* high level was defined based on the cut-offs of the fold changes in tumoral tissue vs. the corresponding ANCT, and the median value of fold changes was set as cutoff.

**Abbreviations:** *NRP1*, neuropilin-1; ANCT, adjacent noncancerous tissue; HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, progesterone receptor; NS, not significant.

###### 

The association between NRP1 protein concentration and demographic and clinicopathological characteristics of patients

  Patient/tumor characteristics   NRP1 concentration (mean values ± standard error of mean, pg/mL)   *P*-value
  ------------------------------- ------------------------------------------------------------------ -----------
  Age (years)                                                                                        
   \<50                           27.99±10.39                                                        0.59
   ≥50                            38.24±16.35                                                        
  Body mass index (kg/m^2^)                                                                          
   25--29                         33.44±13.97                                                        0.92
   \>29                           35.54±14.67                                                        
  Menopause status                                                                                   
   Post                           39.9±14.85                                                         0.39
   Pre                            21.84±8.85                                                         
  TNM stage                                                                                          
   I                              15.71±7.77                                                         0.39
   II                             20.50±11.52                                                        
   III                            57.96±20.81                                                        
   IV                             0                                                                  
  Histological grade                                                                                 
   I                              0                                                                  0.78
   II                             31.62±13.13                                                        
   III                            40.42±16.35                                                        
  Mitotic rate                                                                                       
   1                              28.90±14.54                                                        0.49
   2                              27.89±14.43                                                        
   3                              61.95±26.66                                                        
  Tumor size (cm)                                                                                    
   ≤2                             21.61±14.8                                                         0.607
   2--5                           46.02±17.02                                                        
   ≥5                             26.95±26.95                                                        
  Lymph node involvement                                                                             
   Positive                       66.44±24.33                                                        0.03
   Negative                       18.33±7.32                                                         
  HER2                                                                                               
   Positive                       35.71±14.16                                                        0.52
   Negative                       22.58±9.95                                                         
  ER                                                                                                 
   Positive                       36.67±12.46                                                        0.57
   Negative                       20.21±14.32                                                        
  PR                                                                                                 
   Positive                       27.43±8.44                                                         0.37
   Negative                       46.91±27.21                                                        
  Breast cancer phenotype                                                                            
   Luminal A                      11.42±4.81                                                         0.205
   Luminal B                      52.26±19.57                                                        
   HER2                           0                                                                  
   Triple negative                0                                                                  

**Abbreviations:** NRP1, neuropilin-1; HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, progesterone receptor.

###### 

Relative expression of *NRP1* in invasive, in situ, and normal samples included in the GSE5926 dataset

                Invasive vs. in situ   Invasive vs. normal   In situ vs. normal
  ------------- ---------------------- --------------------- --------------------
  Fold change   0.23                   −1.08                 −1.15
  *P*-value     0.35                   0.11                  0.02

**Abbreviation:** *NRP1*, neuropilin-1.

###### 

Relative expression of *NRP1* in HER2+, basal-like, luminal A, luminal B, and normal-like subtypes compared with normal sample included in the GSE5926 dataset

                HER2+ vs. normal   Basal vs. normal   Luminal A vs. normal   Luminal B vs. normal   Normal-like vs. normal
  ------------- ------------------ ------------------ ---------------------- ---------------------- ------------------------
  Fold change   −1.09              −1.53              −1.55                  −1.15                  −0.92
  *P*-value     0.011              0.001              0.005                  0.0002                 0.14

**Abbreviations:** *NRP1*, neuropilin-1; HER2, human epidermal growth factor receptor 2.
